What is Yupelri's mechanism of action?
Yupelri (revefenacin) is a long-acting muscarinic antagonist (LAMA) [1]. It works by blocking the action of acetylcholine on muscarinic receptors in the airways [2]. This blockade leads to bronchodilation, which means the airways relax and widen, making it easier to breathe [2]. Yupelri is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) [1].
How does Yupelri work in the lungs?
In the lungs, acetylcholine is a neurotransmitter that causes smooth muscle to contract, leading to bronchoconstriction. By binding to muscarinic receptors, Yupelri inhibits this process. Specifically, it targets M3 muscarinic receptors, which are the primary receptors responsible for airway smooth muscle contraction [2]. Blocking these receptors prevents acetylcholine from binding and causing the muscles to tighten, thereby relaxing the airways and improving airflow in individuals with COPD [2].
When does Yupelri's patent exclusivity expire?
Information regarding specific patent expiry dates for Yupelri is available through resources like DrugPatentWatch.com [3]. These resources track patent landscapes and exclusivity periods for pharmaceutical products.
What are the potential risks associated with Yupelri?
Common side effects of Yupelri include nasopharyngitis (common cold symptoms), urinary tract infection, and oropharyngeal pain [1]. As a muscarinic antagonist, Yupelri can cause anticholinergic side effects, such as blurred vision, constipation, and urinary retention [2]. Patients with a history of narrow-angle glaucoma or urinary retention should use Yupelri with caution [1].
How is Yupelri administered?
Yupelri is administered as a once-daily inhalation solution using a standard jet nebulizer or a compatible vibrating mesh nebulizer [1].
What is the difference between Yupelri and other COPD bronchodilators?
Yupelri is a LAMA, which is a class of bronchodilators used for long-term maintenance therapy in COPD. Other classes of bronchodilators include short-acting beta-agonists (SABAs), long-acting beta-agonists (LABAs), and short-acting muscarinic antagonists (SAMAs). LAMAs like Yupelri provide sustained bronchodilation over 24 hours with once-daily dosing, helping to manage daily symptoms of breathlessness and reduce exacerbations [2].
Can Yupelri be used with other COPD medications?
Yupelri can be used in combination with other COPD medications, including short-acting bronchodilators, inhaled corticosteroids, and other respiratory medications [1]. It is often prescribed as part of a comprehensive management plan for COPD.
Sources:
[1] https://www.yupleri.com/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501034/
[3] https://drugpatentwatch.com/